RSV

RSV

RSV

Reaction: Vaccination against RSV in pregnant women protects their babies, but increases the risk of preterm birth, according to a phase III clinical trial

The NEJM publishes the results of a phase III clinical trial conducted by GSK that had to be suspended due to a safety signal. The study shows that newborns of vaccinated mothers had a lower risk of experiencing severe events associated with the respiratory syncytial virus (RSV), but also a higher risk of being born prematurely.

0

Reaction: EMA recommends approval of first vaccine in pregnancy to protect infants against RSV in the first six months of life

The European Medicines Agency (EMA) has recommended marketing authorisation in the European Union for Abrysvo vaccine to protect against respiratory syncytial virus (RSV) disease in infants up to six months of age. It is the first vaccine of its kind indicated for passive immunisation of newborns through administration to the mother during pregnancy. It is also indicated for people over 60 years of age. The European Commission now has to decide on its EU-wide marketing authorisation.

0

Reaction: EMA recommends approval of a new respiratory syncytial virus (RSV) drug for babies and infants

The European Medicines Agency (EMA) has recommended marketing authorisation in the European Union for Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in babies and infants. The agency recommends it during its first RSV season. The European Commission now has to decide on its marketing authorisation across the EU.

0